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ABSTRACT
THE USE OF TARGETED CHARGE-REVERSAL NANOPARTICLES TO
INVESTIGATE NUCLEAR DELIVERY OF FLUORESCENT AGENTS TO CANCER
CELLS: IMPLICATIONS FOR NOVEL PROSTATE AND BREAST CANCER
THERAPY
By Mario Dance DVM
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Pharmacology and Toxicology at Virginia Commonwealth University 2011.
Major Director: Shawn E. Holt, Ph.D., Pharmacology/Toxicology

Nanotechnology has recently emerged as a strong contributor toward research efforts to develop
targeted systems of drug delivery in cancer therapy. Our work investigates the therapeutic
potential of Targeted Charge-Reversal Nanoparticles (TCRNs), a novel nanoparticle with in vitro
evidence of nuclear drug delivery. Using M12 prostate cancer cells, MDA-MB-231 breast cancer
cells, and modified derivatives of these cell lines, we investigated the ability of Folic Acidtagged TCRNs to deliver Nile Red and Dimethyl Indole Redfluorescent (DiR) fluorescent dyes
to the nucleus of cells using confocal microscopy and in vivo biphontonic imaging using
Xenogen® Technology. Confocal imaging with the SCP28 derivative of MDA-MB-231 cells
shows nuclear association of the TCRNs over time, although specific nuclear deposition was
unclear. Biophotonic imaging with M12 and SCP28 xenograft tumors in athymic nude mice
shows retention of TCRNs in animals out to 7 days with minimal localization of TCRNs to
tumor tissues. Our findings suggest that further characterization and manipulation of both the
cells and the nanoparticle is necessary in order to make definitive claims regarding the TCRN’s
ability to deliver fluorescent dyes, and eventually therapeutic compounds, to the nucleus of cells.

Chapter 1
Introduction

Cancer Therapy
The Centers for Disease Control report that cancer claims the lives of more than half a
million Americans every year. Cancer is the second leading cause of death in the United States,
exceeded only by heart disease. Of the various cancers detected in the USA, cancers of the breast
rank highest in women and cancers of the prostate rank highest in men (1). The search for
therapies for all forms of cancer continues with limited success. Traditional approaches in cancer
treatment have focused on killing all actively dividing cells whether or not they were cancer or
normal cells. Further advances have resulted in developing therapies that target destruction of the
cancer while minimizing damage to healthy tissues and cells. Historically, drug and radiation
cancer therapies predominate but advances are frustrated by significant patient toxicities and side
effects due to lack of specificity (2). Various attempts have been made to address these problems
with variable success, indicating a need to investigate novel systems for drug delivery that can
circumvent adverse patient reactions while retaining high levels of drug toxicity that target the
rapidly dividing cancer cells.

Nanotechnology
Engineers refer to Nanoparticles (NPs) as structures that are measured in the nanometer
range (generally less than 100 nm in diameter) (3). In recent years, the field of Nanotechnology
has produced many advances that use NPs with applications in medicine, including aids in
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diagnostics, biomimetic and biohybrid systems, and therapeutics that employ novel drug delivery
techniques. Recently, many promising nanotherapeutics for drug delivery have been developed,
many of which have successfully delivered therapeutic agents in vitro (3-5). These
nanostructures can be loosely categorized based on their chemistry and structure. Liposomes, for
example, are small vesicular structures generally composed of a phospholipid bi-layer with an
aqueous core. This structural arrangement confers properties to the NP that are similar to those of
cell membranes. Liposomes can be loaded with drugs and used to deliver compounds to treat
cancer and other diseases. Similar to liposomes are polymeric micelles, which make use of
organic polymeric structures usually in a uni-layer, spherical configuration. Fullerenes and
nanotubules are structurally and functionally similar hollow structures that can also potentially
be used to carry drugs, although they are more rigid and are typically composed of carbon, metal
(gold or silver), or silicon. Quantum dots are smaller, charged, solid spheres that are typically
used for bioimaging, for carrying drugs that can be tagged to their surface, and for carrying
highly charged materials. Examples of these nanoparticle structures are shown in Figure 1. More
elaborate nanotechnologies are being developed that modify and use these basic structures in
various combinations (6-7).
The use of NPs in medicine, while promising, is not without significant challenges.
Previous studies show that depending on the starting material, the NP is prone to elimination via
the body’s natural immune system primarily through phagocytosis by macrophages (8-10).
Additionally, once NPs enter a living organism, they must fight against an array of natural host
defenses and changes in the microenvironment that can result in their elimination or in the
premature release of their therapeutic contents, ultimately leading to the same toxic side effects
that arise from therapeutic agents delivered by more conventional means. Assuming that NP-
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Dendrimers

Liposomes/Micelles

Nanodots

Nanotubes

Figure 1: Basic Nanoparticle Structures. Nanoparticles have been designed using these basic
structures alone or in combination with each other. Shown above are the regularly branched
Dendrimer structure, the spherical Liposomes/Micelle structure, the solid and charged Nanodot
structure, and the hollow Nanotubule/Fullerene structure.
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carrying drugs are able to survive the host’s immune system, it then needs to retain and deliver
the therapeutic agent to the targeted tissue or body system. Through all of these challenges, the
NPs must circumvent obstacles related to water or fat solubility, membrane permeability, pH
alterations, cell surface receptor interactions, and charge limitations, all of which affect the NP’s
ability to retain the effectiveness of its therapeutic agent (3, 7). The NP that survives host
defenses, that retains its therapeutic agents, and that selectively targets cancer cells for delivery
of their contents will be a powerful asset in cancer therapy. Such a targeted NP would
theoretically reduce patient toxicity by reducing the dosage of the therapeutic agent while, at the
same time, still concentrating the agent and its effect at the site of the cancer.
Despite these challenges, nanotechnology is still a promising alternative to conventional
drug delivery. Studies with liposomes, polymeric micelles and nanotubules show results
indicating successful delivery of different therapeutic agents to cells especially under in vitro
conditions (3-4, 11-12). While some NP-mediated therapies have begun to enter clinical trials (6,
13-15), most NPs have shown very limited success for drug delivery in vivo due, in part, to the
aforementioned fact that once the NPs are introduced into a living organism, they are subject to
natural host defenses and microenvironment changes that result in their elimination or in a
premature release of their therapeutic contents (3, 16). If NPs could target not only the cell but
the nucleus of the cell, this could potentially magnify a drug’s therapeutic potential
exponentially. The focus of our study was to investigate the therapeutic potential of the Targeted
Charge-Reversal Nanoparticles (TCRNs) to deliver agents to the nucleus of breast and prostate
cancer cells.
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Targeted Charge-Reversal Nanoparticles
TCRNs are unique NPs, and studies suggest they can successfully deliver
chemotherapeutic agents to the nucleus of human ovarian carcinoma cells (SKOV-3) in vitro (11,
17). The TCRNs are based on a polymeric micellar system that has been developed by Dr.
Youqing Shen at the University of Wyoming. Dr. Shen is a noted polymer chemist with
significant experience in generating NPs for specific delivery of compounds to the nucleus of
eukaryotic cells. The NP used for our experiments is constructed using 3 different polymers that
combine to form a pH-responsive structure, which has the potential to deliver drug past the
cytoplasm into the nucleus of the cell. The NP is made up of a negative-to-positive chargereversal polyethyleneimine (PEI) polymer outer layer that responds to pH changes, which is only
triggered at specific locations related to the cell. The TCRNs reportedly undergo a
conformational change during exposure to the extracellular acidic environment (pH<7), which is
often found around inflamed or neoplastic tissues and within the acidic lysosomal environment
(pH 4–5) during cell entry (11, 17). In general, negatively charged polymers have little
interaction with blood components, so the PEI polymer has been used extensively in vivo for this
purpose (3, 18). There is a second hydrophobic polymer, polycaprolactone (PCL), joined with
the PEI that together combines to stimulate the formation of the micellar system responsive to
changes in pH. Previous experiments (19) showed that the micelles formed by this polymer
combination, when linked with a FA moiety (the third component of the terpolymer), can
navigate the pH shifts in blood, tumor, and intracellular liposomal environments in such a way as
to carry drug to the nucleus of the cell (Figure 2). These in vitro results found that TCRNs
carrying doxorubicin (DOX) are more effective at killing SKOV-3 cancer cells than free DOX
alone (11). If this experiment can be duplicated using other cell lines while carrying different
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Figure 2: Schematic representation of the movement of TCRNs into the cell. TCRNs
move out of vascular circulation into the tumor microenvironment where they undergo pH and
charge alterations that permit them to move into the cell to deposit their contents into the
nucleus. Image used with permission (Dr. Youqin Shen).
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therapeutic agents in both in vitro and in vivo systems, then this TCRN system could have major
therapeutic implications for many cancer types.
For our studies, TCRNs were conjugated with folic acid (FA) to employ the folate
receptor (FR) as a target for attachment to and entry into the cell. FAs (also known as
pteroylglutamic acid, vitamin B9, Bc folacin, and folate) are essential cofactors for many
biochemical reactions involving one-carbon metabolism, including purine and thymidine
synthesis, remethylation of homocysteine to methionine, and conversion of serine to glycine. The
role of this vitamin in the production of precursors for DNA synthesis and repair makes it
essential for proliferating cells (20-21). The high affinity FR is a membrane-associated
glycoprotein that is preferentially expressed in cancers of epithelial origin (20, 22-23), which
makes it an ideal candidate for many novel targeted drug therapies and is the focus of many NP
driven studies (4, 21, 24).
FAs are used in many cellular processes, but the hydrophilic and anionic nature of FAs,
at physiologic pH, impedes their passive diffusion through the plasma membrane. Therefore,
most cells acquire the FA needed for normal cell processes primarily by two separate
mechanisms. One involves a transmembrane transporter, known as the reduced folate carrier
(RFC), named because of its inability to bind FA, the nonphysiologic, oxidized form of the
vitamin. This ubiquitously expressed RFC protein has a high affinity for 5methyltetrahydrofolate (5-MTHF) (Kd 3– 4.0µmol/L), which is the predominant FA formulation
found in serum although it has a much lower affinity for FA (Kd 5 100–200µmol/L). The RFC is
also present throughout development and in normal adult tissues, despite significant variability in
its expression levels among tissue types (25-26).
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The other primary FA uptake system uses a glycosyl-phosphatidylinositol (GPI)anchored protein known as the FR that transports FAs into the cytosol via fluid-phase
endocytosis. The physiologic function of the FR in adult tissues has largely remained a mystery
since, in addition to its narrow tissue distribution, the FR is predominantly expressed on the
apical (luminal) surface of polarized epithelial cells, where it is not in contact with circulating
FA. This FR binds its ligands with very high affinity, having a Kd of 0.4nmol/L for FA and
3nmol/L for 5-MTHF (25-27).
There are four isoforms of the FR (FRs −α, −β, −γ and −δ ) that vary somewhat in
sequence, ligand preference, and tissue distribution, such that only one isoform, designated FR-α,
is thought to be physiologically relevant with respect to the targeting of solid tumors in therapy
because of its tendency to be over expressed in many tumor types (20). FR-α and FR-β are
membrane-associated proteins, whereas FR-γ lacks the signal for GPI-anchor attachment and is
constitutively secreted (27-28). FR-β has some clinical relevance as it is expressed in later stages
of normal myelopoiesis and in placenta, spleen, and thymus. FR-β is also expressed in leukemic
blasts in chronic and acute myelogenous leukemia (27). Because we focused primarily on the
function of the FR-α in our cells, unless stated otherwise, all references to the FR will signify the
more physiologically relevant FR-α.
As stated, the FR is expressed at the luminal surface of polarized epithelial cells of
normal adult tissues including proximal kidney tubules, type I and II pneumocytes in the lungs,
choroid plexus, ovary, fallopian tube, uterus, epididymis, submandibular and bronchial salivary
glands, and trophoblasts in placenta, as well as the basolateral membrane of retinal pigment
epithelial cells (25). Several malignant tumors are known to overexpress FR, including nonmucinous adenocarcinomas of the ovary, uterus and cervix, testicular choriocarcinoma,
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ependymal brain tumors, malignant pleural mesothelioma, and nonfunctioning pituitary
adenocarcinoma. In other malignant types of cancer such as breast, colon, and renal cancers, FR
over-expression is less frequent but still common enough to be exploited (27-28) While virtually
every potential drug target protein in malignant cells is also expressed in at least a few critical
normal tissues, this differential anatomic distribution of FR renders it generally inaccessible
directly through the blood stream in normal tissues, making it a preferred target to effectively
address the problem of tumor specificity. Moreover, the receptor specifically and tightly binds a
small water soluble molecule, FA, that is amenable to chemical conjugation of small and large
drug molecules or nanoparticles without disruption of its binding properties (18, 27).
In vitro studies suggest that the TCRN NPs attach to cells using the FR and then are later
brought into the cell via endocytosis (Figure 2) (11, 17). The proposed mechanism for this
attachment hinges on the metabolic and inflammatory processes that occur near the actively
growing tumor and the increased vascular permeability in the tumor microenvironment. It is
hypothesized that when the blood borne negatively charged TCRN carrying drug circulates near
this weakly acidic microenvironment, it extravasates, becomes positively charged, and is
internalized within the cell either by receptor-mediated endocytosis or by adsorptive endocytosis
(endosome). Once the NP gains entry into the cell by either mechanism, it is transferred to the
strongly acidic lysosome where the PEI/amide outer layer is hydrolyzed into PEI, the NP
undergoes a conformational change, and the modified TCRN is then released from the lysosome
to subsequently enter the nucleus for drug delivery (11, 17).
In this study, we aim to verify this claim in additional cell lines and to confirm that
TCRNs are actually able to target and deliver fluorescent dyes to breast and prostate cancer cells
in an in vitro environment. Further, we hope to show that these TCRNs are also uniquely able to
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deliver fluorescent dyes, not simply to the cytoplasm, but to the nucleus of breast and prostate
cancer cells. Our central assertion is that TCRN’s are capable of delivering fluorescent agents to
the nucleus of carcinoma cells. TCRN delivery can be manipulated by exploiting pH changes in
the microenvironment of the cell and by utilizing the cell surface FR as a mechanism for cellular
delivery in an in vivo and an in vitro environment.

Fluorescent Imaging
This study makes use of several imaging technologies, all of which are based on the same
fundamental principles that govern our ability to see light. Photons that strike objects are
reflected or absorbed, creating a signal that registers on an image transducer. The vertebrate
retina, which absorbs and transduces photon signals to the brain producing an image, is the
simplest example of this principle. Engineers take this basic principle and translate it into
technology that permits visualization of things that are not visible with the unaided eye. We can
visualize internal organs macroscopically using technologies that manipulate sound (ultrasound
imaging), X-ray radiation (radiographic imaging), and ionizing radiation (magnetic resonance
imaging). On a microscopic level, manipulating electrons and lasers helps us to magnify images
that are beyond the ability of ordinary light microscopes. All of these technologies can be further
enhanced using contrasting agents that further amplify or modify the signal being recorded.
Radiography, for example, uses barium or iodine contrast agents to improve visualization of
organs, while microscopy uses fluorescent agents to improve visualization of cellular structures
and organelles (29-30).
In our study, we use optical fluorescent imaging technology and Xenogen Imaging
Technology (XIT) to confirm the ability of the TCRNs to deliver their contents to the cell.
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Confocal microscopy is an advanced form of light microscopy, useful for viewing fluorescently
labeled cellular structures. An object of interest is labeled or tagged with a fluorophore that,
when illuminated with light of a specific wavelength, will absorb the light and emit a signal at
another longer wavelength that is detected by the optical imaging device and transmitted as
color. Confocal microscopy uses this same principle with light generated by lasers of different
wavelengths that scan the sample in a more focused manner. The illumination is confined to a
diffraction-limited spot in the specimen and the detection is similarly confined. All of this
produces an ‘optical sectioning’ effect, in which the glare from out-of-focus regions is almost
completely eliminated and the image sharpened (31).
Bioluminescent in vivo imaging using XIT, also known as biophotonics, employs similar
principles to image macroscopic objects in real time. This in vivo imaging is a noninvasive
technique using bioluminescent and fluorescent endogenous reporters or exogenous probes to
monitor molecular and biological processes. In the simplest terms, it is a device with a sensitive
camera that measures light produced by biological or chemical moieties. The object being
imaged is placed on the sample stage where the fluorescent signal passes through the animal to
the lens and filters and, ultimately, to the camera. The light is detected by the sensitive camera
and superimposed over a normal camera image of the animal/object (Figure 3). It is a noninvasive time/space visualization of biological processes inside of a live animal, relying on light
producing optical reporters such as luciferase, fluorescent proteins, fluorescent dyes and
conjugates. Genes encoding luciferase and fluorescent proteins can be engineered into cells (e.g.,
cancer cell lines and infectious disease agents) and into animals (transgenic mice and rats),
which enables them to produce light that can then be visualized through the tissues of a live
animal using specialized Xenogen imaging equipment and software (30, 32). Most commonly,
12

CCD camera
Filter Wheels
Lenses

Heated Sample
Stage

Chiller and
Camera controller

Figure 3: IVIS® Spectrum Imaging System. On the left is the Xenogen machine positioned
next to its anesthesia vaporizer and computer for image analysis. On the right is a schematic of
the machine’s internal imaging components. Image is courtesy of Caliper Life Sciences.

13

the imaging device measures luminescent signals that are produced when natural biological
substances, typically luciferin or green fluorescent protein (GFP), are injected into or otherwise
expressed in animals and excited by a substrate-driven enzymatic processes to produce light at
different wavelengths. Similarly, the device can be used with fluorophores or fluorescent
reporters that come in a wider variety of forms: expressed proteins, dyes, microspheres, and NPs.
Visualization of fluorescent reporters does not require the administration of a substrate and can
be used in both live and fixed cells/tissues (29). This highly sensitive dual bioluminescence and
fluorescence imaging systems has the advantage of allowing significantly fewer animals to be
used due to the fact that the entire process is non-invasive. Additionally, this technology allows
us to follow the development of tumors and to monitor the intensity of any fluorescent signal
present in the tumor over time in the live animal. The final image produced by XIT is a
composite image composed of a photographic image of the object superimposed over a
luminescent image with intensity of luminescence represented by gradations in color (Figure 4).
In this study, we aimed to verify the nuclear delivery claims of the TCRNs by integrating
a fluorescent dye into the core of the NP and working to show that this dye is being deposited
into our cells. Our goal was to show that the dye is ultimately deposited in the nucleus of cancer
cells, suggesting that the TCRNs will function similarly when carrying chemotherapeutic agents.
In so doing, we expected to demonstrate by proof of principle the potential use of TCRNs for
delivery of therapeutic agents into cells, further suggesting that TCRNs can be used to reduce the
dosage of chemotherapeutic agents that often target the DNA machinery in the nucleus and are
highly toxic to patients.
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Figure 4: Construction of the Xenogen Image. Standard images are composed of two
superimposed images: Photographic image + Luminescent image = Overlay image. These are
screen shot images of what is seen when measurements are taken using the Xenogen imager.
Image is courtesy of Caliper Life Sciences.
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The overall hypothesis and specific aims are as follows:

Hypothesis: We propose that TCRNs carrying fluorescent dyes will selectively deposit their
contents into the cytoplasm and the nucleus of carcinoma cells using the FA/FR interaction
producing changes in fluorescent signaling as observed by in vitro and in vivo assays.

Specific Aim: To characterize and verify the FR profile of our prostate and breast cancer cell
lines in order to 1) demonstrate TCRN dye delivery and 2) correlate TCRN function with the FR
using differences in fluorescent signaling within the cytoplasm and the nucleus of tumor cells.
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Chapter 2
Materials and Methods

Cell Lines and Culturing: Several cell lines were used for this study: M12 prostate cancer cells;
M12-luc cells, which are prostate cancer cells stably transfected to express luciferase; MDAMB-231 breast cancer cells; SCP28-S4-Tet-Duo breast cancer cells, which are also engineered to
express luciferase; BJ foreskin fibroblast (BJF); and adipose derived stem cells (ASC). BJ
fibroblasts were grown in high glucose Dulbecco's modified Eagle's medium (DMEM;
Invitrogen) supplemented with 10% cosmic calf serum (Hyclone) and 1%
Antibiotic/Antimycotic Solution (ABAM; Sigma-Aldrich). ASC-8 at PD10 were previously
isolated in our laboratory from a lipoaspirate obtained from the VCU Surgery Department in
accordance with VCU IRB procedures for medical waste. ASC-8 cells were grown in low
glucose DMEM supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1% ABAM.
Both the M12 and the M12-luc cells were cultured in Roswell Park Memorial Institute (RPMI;
Invitrogen) medium supplemented with 0.03mg/ml gentamicin+ 0.3mg/ ml L-glutamine + 0.1%
ITS (Insulin/Transferrin/Selenium; VWR Radnor, PA) + 5% FBS. MDA-231 and SCP28-S4Tet-Duo breast cancer cells were cultured in RPMI medium supplemented with 0.03mg/ml
gentamicin + 0.3mg/ml L-glutamine + 5% FBS.
The principle cell lines used for all of the experiments are the M12 and M12-luc prostate
cancer cell line, and the MDA-MB-231 and SCP28 breast cancer cell lines. The M12 cell line is
a tumorigenic, metastatic subline of human prostate epithelial cells previously immortalized by
transfection with the SV40T antigen gene, developed by Dr. Joy Ware by sequential passage of

17

the cells in male athymic nude mice (33). The SCP is a single cell-derived subline of MDA-MB231 that is highly osteolytic and metastatic, but it is also engineered for bioluminescent imaging.
This cell line was engineered to express Renilla luciferase under a constitutively active
cytomegalovirus promoter for quantitative measurement of metastatic tumor burden in vivo
through noninvasive bioluminescence imaging using coelanterazine as the substrate. It also
expresses firefly luciferase using D-luciferin as the substrate (34).

Western Blot Analysis: To confirm the presence of the FR in M12, M12-luc, MDA-231, BJF,
and ASC cells, we performed Western analysis for FR and β-actin (as an internal control). Cells
were trypsinized and then lysed with Radio-Immunoprecipitation Assay (RIPA) buffer
supplemented with protease inhibitor (Sigma) for 30mins on ice. Whole cell lysates were
prepared from each of these cell lines and subjected to five 20 second pulse intervals of
sonication at power level 2 using a Misonix 3000 sonicator in order to shear the genomic DNA
prior to gel electrophoresis. The samples were placed on ice between treatment intervals. After
sonication, lysates were clarified by centrifugation at 11,000 x g for 20mins. The resulting
supernatant was collected and analyzed for total protein content using a Biorad Protein Assay kit
and a spectrophotometer. Protein samples were treated with non-reducing 4x sample buffer (4%
SDS, 20% glycerol, 0.004% bromophenol blue, 0.125M Tris HCl, at pH 6.8) at 85°C for 10mins
and then loaded (25μg total protein per sample) on a 10% sodium dodecyl sulfate
polyacrylamide gel (SDS-PAGE) followed by electrophoresis for approximately 1.5 hours.
Following SDS-PAGE, the gel was transferred to nitrocellulose membrane by electroblotting at
100 volts for approximately 1 hour. The membrane was blocked using 5% non-fat milk for 1
hour at room temperature, followed by multiple washes with PBS+1% Tween-20 (PBS-T). The
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blot was incubated with primary antibodies (anti-folate, at 5µg/ml; Enzo Life Sciences; anti-βactin at 1μg/ml; Sigma) for 1 hour at room temperature, followed by multiple PBS-T washes.
Secondary antibody (goat anti-mouse conjugated to horseradish peroxidase, at 1µg/ml dilution;
#172-1011 BIO-RAD, Hercules CA) was used to probe the blot for 1 hour at room temperature,
followed by extensive washing with PBS-T. Pierce SuperSignal (luminol and peroxide
solutions) was used for detection, and the blot was exposed to Kodak OMAT film and
developed. We used this non-reducing protocol because the FR is a complex cell surface protein
whose conformation is very sensitive to reducing reagents, and our particular antibody was not
able to recognize the FR protein after it had been treated with a reducing protocol. We needed to
adjust the normal Western assay to eliminate exposure to reducing agents so that our primary
antibody could recognize the protein.

Fluorescence-Activated Cell Sorting (FACS) Analysis: To quantify and further characterize
the presence of the FR on the cell surface of the M12, M12-luc, MDA and SCP cell lines, we
used FACS analysis. The cells were cultured in cell-specific media and then harvested with
0.25% (w/v) trypsin-0.1% (w/v) EDTA solution and counted, adding approximately 1x106 cells
to sample tubes. The cells were incubated in FACS buffer (PBS + 1% FBS) at room temperature
for 15mins and then on ice for 10mins. Following this stabilization period at room temperature to
allow cell surface proteins to recover from trypsin treatment, the cell suspension was treated with
primary mouse monoclonal antibody (anti-folate, at 5µg/ml; Enzo Life Sciences, Plymouth
Meeting, PA) and incubated for 30mins on ice rocking gently. Cells were washed 3 times with
FACS buffer and then treated with secondary antibody (goat anti-mouse IgG conjugated to
Alexa 488 at 1µg/ml; A11029 Invitrogen) on ice rocking gently. Cells were washed again 3
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times in FACS buffer and then counted in BD FACSCanto II Flow Cytometer using DIVA
software for signal analysis.

Fluorescent Microscopy: To assess the relative expression level of the folic acid receptor in
vitro, 1x104 cells were seeded and were grown on an 8-well chamber slide to 60-70%
confluency. The cells were rinsed twice with PBS and fixed with 4% paraformaldehyde for
10mins at room temperature. The cells were then washed twice in PBS and permeabilized with
0.5% NP-40. After washing again, the cells were blocked with a mixture of Cold Water Fish
Gelatin with BSA dissolved in PBS (PBG) for 1 hour followed by overnight incubation at 4ºC
with primary mouse monoclonal antibody (anti-folate, at 2.5μg/ml; Enzo Life Sciences) diluted
in PBG. The cells were then washed with PBG 3 times and treated with secondary antibody (goat
anti-mouse IgG conjugated to Alexa 488 at 1μg/ml dilution; A11029 Invitrogen) also diluted in
PBG. The cells were next washed 3 times in PBG and then covered with embedding media
mixed with DAPI (Sigma-Aldrich, St. Louis, MO) and Vectashield mounting media (Vector
Laboratories, Burlingame, CA). We used 200μg/ml of DAPI in a 1:1000 volume dilution with
mounting media.

Survival/Cytotoxicity Assay: To assay potential toxic effects of dye-loaded TCRNs, 1x104 M12
or SCP cancer cells were seeded (~50-70% confluency) in 6-well chambers filled with 1ml of
their respective media. The cells were allowed to acclimate and attach to the plates for 2-4 days.
The cells were treated with TCRNs at varying concentrations for 6-168 hours. At each time
point (6, 24, 48, 72 and 168 hrs), cells were collected after treatment with 0.25% (w/v) trypsin0.1% (w/v) EDTA (Mediatech, Inc .,Manassas, VA), centrifuged, and resuspended in 2mls of
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respective culture media. Live/dead counts were performed using a hemocytometer after Trypan
Blue treatment (4% w/v) in normal saline (Mediatech Inc) at a dilution of 0.5mls cell suspension
with an equal volume of 50% Trypan blue. Cell survival was evaluated at defined time intervals
of exposure by live cell counts expressed as a percentage of total cells counted. Using Nile Red
(NR) and Dimethyl Indole Red (DiR), cells were treated to the following dilution scheme: NR
(PBS, 3.4µg/ml, 0.68µg/ml, 0.34µg/ml. 0.034µg/ml, and 0.0034µg/ml), DiR (PBS, 40µg/ml,
8µg/ml, 4µg/ml, 0.4µg/ml, and 0.04µg/ml). It should be noted here that when calculating TCRN
doses and concentrations, one must consider both the concentration of the NP and the
concentration of the dye contained in the NP. For the sake of simplicity, all concentrations given
refer to the concentration of the dye contained within the NP since this would, by inference,
represent the concentration of drug administered to the animals would.

Confocal Microscopy: In 6-well chambers filled with 1 ml of respective media, 1x104 SCP cells
or M12 cells suspended in 0.1mls of media were seeded (50-70% confluency) onto 22mm2 acid
cleaned and flame dried cover slips. The cells were allowed to acclimate and attach to the slides
for 2-4 days. We delivered a standard 0.1 ml volume of the various NP dilutions into 2.8ml of
RPMI culture media in each well. The cells were treated with the dye loaded TCRNs at various
dye concentrations at time points ranging from 6-168 hours. At each time point, cells were fixed
with 4% paraformaldehyde in PBS for 10mins, washed with 0.3M glycine in PBS (3x) for
10mins, and mounted on a slide with DAPI (Sigma-Aldrich, St. Louis, MO) and Vectashield
mounting media (Vector Laboratories, Burlingame, CA) using 200µg/ml DAPI in a 1:1000
dilution with mounting media. Slides were stored in a light proof box at 4ºC until imaged. Cell
imaging was performed using either a Zeiss LSM 510 META confocal microscope or the Leica
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TCS-SP2 AOBS confocal microscope. Images were acquired and processed with imaging
software provided by the respective microscopes. For our confocal imaging, we originally chose
DiR as our fluorescent dye because it is lipophilic and easily intercalates with cell membrane
structures. It has a higher emission spectra enabling better tissue penetration during Xenogen
imaging. DiR emits in a range that is near infrared fluorescence (excitation 750nm/emission
780nm). It is also a lipophilic carbocyanine that is weakly fluorescent in water but highly
fluorescent and quite photostable when incorporated into membranes. It has an extremely high
extinction coefficient and short excited-state lifetimes (~1 nanosecond) in lipid environments
(35). Once applied to cells, the dye diffuses laterally within the plasma membrane (36). This dye
was recommended and was ideal for the in vivo component of our experiments, but, with the
confocal microscopes that are commonly used for our in vitro experiments, the spectra of
excitation of this dye is too high for the lasers used. Furthermore, using the laser that is most
suited for this dye could also impact cell architecture and distort our images. To address this
problem, we switched to using Nile Red (excitation 559/emission 636) for the preliminary in
vitro experiments. NR is a phenoxazone dye that fluoresces intensely in organic solvents and
hydrophobic lipids. The fluorescence, however, is fully quenched in water and therefore acts as a
fluorescent hydrophobic probe (37).

In vivo imaging: The tumor mouse model was generated by SC injection of 5×106 M12 or SCP
cells in PBS into the dorsolumbar region of male and female athymic nude mice (5–6 weeks
old). The mice were subject to imaging studies when the tumor volume reached a size around 1.0
cm3. All animal experiments were performed in compliance with VCU’s Institutional Animal
Care and Use Committee (IACUC). This in vivo experiment used subcutaneous M12 and SCP
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xenograft tumors in athymic nude mice. Once tumor sizes reached an initial diameter of about
0.5-1.0cm, the mice were treated intravenously with TCRNs loaded with dye at 2 different
concentrations. Briefly, using a total of 5 mice per treatment group, animals were injected
intravenously once in the tail vein or the retro-orbital plexus with approximately 100μl of the dye
loaded TCRN mixture at various concentrations. At predetermined time points (from 0 to 168 h
post-injection), these mice were anesthetized with a ~3% isoflurane/oxygen mixture and placed
in the dark chamber of the IVIS Imaging System 200 Series® in vivo Xenogen® imaging
instrument. The image was created using the ICG Bkg/ICG and the GFP Bkg/GFP excitation and
emission filters. The quantitative distribution of TCRNs in the animal was determined by
fluorescence measurements using vendor software. The total fluorescence efficiency for the
tumors was measured using a uniform region of interest (ROI) applied to each tumor with
background from the control value. Image analysis was made using Living Image® software
v2.60.1.
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Chapter 3
Results

Hypothesis: We propose that TCRNs carrying fluorescent dyes will selectively deposit their
contents into the cytoplasm and the nucleus of carcinoma cells via the FA/FR interaction,
producing changes in fluorescent signaling as measured and visualized by in vitro and in vivo
assays.

Specific Aim 1: To characterize and verify the FR profile of our prostate and breast cancer cell
lines in order to make meaningful correlations regarding the TCRN’s ability to target our cells
using this receptor.

Rationale: Our TCRNs are tagged with a FA moiety in order to exploit the fact that several
malignant tumors are known to over express the FR. Once we confirm the FR profiles of our
cells, we can then use the FR/FA interaction to selectively target cells using the TCRNs allowing
us to attach even greater clinical relevance to our NPs.

In vitro assays verify differential FR expression on breast and prostate cancer cells
There are many factors influencing the successful delivery of TCRN agents to the cells.
Our experiments focused on one of those factors, the expression of FRs on the cell surface of the
prostate and breast cancer cells. TCRNs are designed to use the FR to target cells for delivery of
their contents. Using multiple protein-based assays, we verified and quantified the presence of
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the FR on the cells selected for this study. Western results confirm that the FR protein is
expressed by breast and prostate cancer cells, but to varying degrees. As expected, our results
showed that the breast cancer cell lines (SCP and MDA-231) express the FR at higher levels than
the prostate cell lines (M12 and M12-luc) (Figure 5) (12, 24). It is also worth noting that our
Western showed that the BJ fibroblasts also strongly expressed the FR. Based on reports in the
literature, we would not expect that this protein would be expressed primarily on the cell surface,
although this finding may suggest the expression of the FR in the cytosol since whole cell lysates
were used. To confirm this, we would need to subject the BJ fibroblast cells to the FACS assay
and a radioligand binding assay for comparison with our breast cancer prostate cancer cells.
The results of the Western were further confirmed with a FACS analysis showing the
prevalence of the FR on the cell surface of intact cells. Flow cytometry is broadly defined as a
system for measuring and then analyzing the signals that result as particles flow in a liquid
stream through a beam of light (38). Treated cells are collected and suspended in PBS, and the
cells are then injected into the flow cytometer. When coupled with fluorescent probes, it enables
Fluorescence-Activated Cell Sorting (FACS) analysis, which is an ideal tool for sorting
heterogeneous mixtures of cells based on their cell surface profile. This technology can sort cells
according to their fluorescent intensity and size. In this FACS analysis, the cells were probed
with primary antibody against the FR and a secondary antibody flagged with the Alexa 488
fluorophore. Our FACS analysis for the FR (Figures 6-10, summarized in Table 1) showed that
the breast cancer cell line (MDA-MB-231) had increased levels of FR when compared with the
prostate cell lines tested (M12 and M12-luc). Based on this data we would expect that our FAlabeled TCRNs would be able to interact with these FR-expressing cells in a way that would
permit them to transport their contents into the cells. Further, we would expect that cells with a
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Figure 5: Western Blot Assay Probing for the Folate Receptor (FR). The Western blot
shows confirmation of the literature’s claim that prostate cancer cell lines (M12L and M12)
express the FR to a lower degree than the breast cancer cells lines (MDA and SCP). BJ
fibroblast and ASC cells were included as normal cell comparisons, with minimal expression in
ASCs and higher expression in BJ. Multiple independent protein isolations from each cell type
are shown. The loading control used is β-actin.
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FACS: Null Control

Figure 6: FACS Analysis Showing Poor Alexa Fluor-488 Signal in Null Control. These
data sets show that M12 prostate cancer cells not probed with any primary or secondary
antibodies have a very low fluorescent intensity and, therefore, were used to determine
background signal (i.e., autofluorescence) generated. Similar results were obtained with the
MDA-MB-231 cell types.
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FACS: Negative Control (No 1° Ab)

Figure 7: FACS Analysis Showing Poor Alexa Fluor-488 Signal in Negative Control.
This data set shows M12 prostate cancer cells that were not incubated with a primary antibody
but were probed with the secondary antibody alone. These results were used to determine
background signal generated by cells as a consequence of exposure to secondary antibody
only, as well as any fluorescence associated with experimental manipulation. Similar results
were obtained with the MDA-MB-231 cell types.
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FACS: Positive Control (CD29)

Figure 8: FACS Analysis Showing Strong Alexa Fluor-488 Signal in Positive Control. This
data set shows M12 prostate cancer cells that were probed with anti-CD29 primary antibody
and the secondary antibody. This sample shows that our FACS assay is optimized and able to
detect a ubiquitously expressed cell surface antigen when probed. Similar results were obtained
with the MDA-MB-231 cell types.
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FACS: Folate Receptor

Figure 9: FACS Analysis Showing Weak-Moderate Alexa Fluor-488 Signal in a Probe
for the FR (M12). This data set shows M12 cells that were probed with the aim of detecting
cell surface FR. Cells were probed with anti-FR primary antibody and the secondary antibody.
This experiment shows us the strength of the FR protein expression on the cell surface.
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FACS: Folate Receptor

Figure 10: FACS Analysis Showing High Alexa Fluor-488 Signal in a Probe for the FR
(MDA-MB-231). This data set shows MDA-MB-231 cells that were probed with the aim of
detecting cell surface FR. Cells were probed with anti-FR primary antibody and the secondary
antibody. This experiment shows us the strength of the FR protein expression on the cell
surface.
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Table 1. Summary of FACS Data

Table 1: Summary of Data from FACS Experiments. P1 indicates the percentage of the total
parent population of cells that were assayed for the receptor in question. P2 indicates the average
strength of the Alexa 488 signal generated by the cells that were assayed from this subpopulation.
P3 indicates the percentage of cells that produce a signal that are positive for the receptor being
probed after accounting for background signal. These results confirm what we see in the western
and IHC assay characterization of FR. MDAs express FR to a higher degree than the M12’s.

32

stronger FR profile would have a measurably and significantly greater ability to internalize the
TCRNs than cells with a weaker FR profile. The difference in FR expression was confirmed
definitively using live cell FACS analysis and less definitively using IF Microscopy (Figure 11).
Together our data suggests that the FA/FR system will be useful for our TCRNs to deposit their
fluorescent dyes in FR-expressing carcinoma cells when compared with those cells that express
lower levels of FRs.
In our FACs assay, we also probed for the prostate specific membrane antigen (PSMA)
(see Table 1). Recent studies have shown that this membrane bound protein can also be used by
cells to transport FA into cells (39). The presence of this protein in our cells could potentially
influence the uptake of our FA conjugated TCRNs, especially with respect to our prostate cancer
cells that show a reduced level of FR compared to the breast cancer lines. While we did not
perform any experiments that would specifically target this protein using the TCRNs, it is
important to factor its expression into any results that make use of the FA/FR interaction as
PSMA can also internalize FA. The presence of this protein in our M12 cells cells could
potentially lend greater weight to the importance of the FA moiety on our TCRNs and provide an
alternative method for exploiting this interaction in other cells, especially prostate cancer cells.
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M12‐Luc

M12
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Figure 11: Immunocytochemistry Assay Showing Folate Receptor expression in M12
prostate and MDA-MB-231 breast cancer cells. Shown, imaged at 60x magnification, is a
stronger fluorescent signal produced by cells when probed for the FR. FR protein is detected
in the 3 cell lines but seems to be slightly stronger in MDA-231 cells. Control cells were
probed with 2° antibody alone.
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Specific Aim 2: To demonstrate TCRN dye delivery to cells correlating TCRN function with the
FR using differences in fluorescent signaling within the cytoplasm and the nucleus of our cells

Rationale: Because there are studies that suggest that the TCRNs can carry and deposit their
contents into the nucleus of cells grown in vitro, we believe that if this data can be verified in
additional cell lines using different agents in vitro and then in vivo we can then infer that the
TCRNs have the potential to be used to carry chemotherapeutic agents in a clinical setting.

In vitro cytotoxicity suggests optimal TCRN dose
In general, any novel NP is considered to be a potential biological hazard, making it
critical to evaluate any potential in vitro cytotoxicity related to the TCRNs that could interfere
with our study. Once safety can be demonstrated using TCRNs carrying biologically inert dyes,
then we can infer that the TCRNs may be used to carry other more biologically active agents that
may have their own cytotoxic effects, which will also enable us to restrict our interpretations
regarding efficacy to the agent and not to the carrier. Using a dose response curve, we were able
to determine an optimal concentration of the TCRNs that enabled normal cell proliferation,
which suggests a starting point for an in vivo dosage for assessing toxicity in mice.
This experiment provided optimal conditions for cell growth in the presence of the dyeloaded TCRNs. The experiment shows that the optimal dilution of dye for cell survival of both
cell types was the 1:100 dilution of the nanoparticles, which corresponds to the 0.4µg/ml
treatment for DiR and the 0.034µg/ml treatment for NR (Figures 12, 13). Cell survival was also
highest at 24 and 48 hrs post inoculation. Our data demonstrate that TCRNs loaded with dye do
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Figure 12: Percent viability of SCP breast cancer cells treated with dye loaded TCRNs over
time. These graphs show that the highest dosage of the dye loaded TCRNs that can support cell
growth over time without adverse affects is 0.034µg/ml (Nile Red) and 0.4µg/ml (DiR). This
suggests a dose dependent toxic affect associated with the TCRNs in this cell line.
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Figure 13: Percent viability of M12 prostate cancer cells treated with dye loaded TCRNs
over time. These graphs show that the highest dosage of the dye loaded TCRNs that can
support cell growth over time without adverse affects is 0.034µg/ml (Nile Red) and 0.4µg/ml
(DiR). This suggests a dose dependent toxic affect associated with the TCRNs in these cells.
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impact the survival of both the SCP and the M12 cell lines and that there is a toxic effect related
to the TCRNs especially at the higher concentrations of dye. The results indicate that the highest
concentration of DiR for both cell types is 0.4μg/ml and 0.034μg/ml for NR. These values
correspond to NP concentrations of 30μg/ml and 0.3μg/ml respectively.

Confocal Microscopy shows nuclear association of TCRN dye.
The confocal assay of this experiment was complicated by many technical challenges.
The TCRNs have a very short shelf life (approximately 3 weeks) and so many of the in vitro and
in vivo experiments had to be performed at the same time once the TCRNs were made. There
were also technical issues associated with the confocal microscopy, which was discovered after
processing the images. The use of the Leica microscope provided little, if any, capability to
distinguish subcellular localization (Figure 14, lower panels), while the Zeiss confocal
microscope showed definitive localization of the dye-loaded TCRNs Figure 14, upper panels).
Further examination of the confocal images suggested that, at a minimum, the TCRNs can enter
cells and deposit their contents into the cytoplasm. It appears that they travel and associate with
the nucleus and possibly deposit a fraction of their contents into the nucleus (Figure 14). The
peak effect noted in this experiment parallels the survival experiment and shows that the
strongest fluorescent signal for the NR dye occurs in the 1:100 dilution between 24-72 hours post
incubation with the TCRNs.

In vivo parenterally administered TCRNs fail to show tissue specificity.
Extrapolating in vivo dosing from our in vitro experiments was a challenge, but, in this
experiment, it was useful to correlate the concentration of the TCRNs with the dye within the
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Figure 14: Zeiss and Leica confocal images of SCP28 cells grown in vitro at 1:100 dilution
of NR loaded TCRNs and 48hrs post treatment. Representative images of the same cells taken
with 2 different microscope systems showing the qualitative differences noted between the two
systems. The top images were obtained using the Zeis microscope. Nuclei are stained with DAPI
and nucleus is dotted with red staining likely resulting from deposition of NiR dye. Magnified
image is shown to the right, with punctuate TCRNs localizing in the perinuclear region of the
cell. The bottom images were obtained using the Leica microscope. The image shows that the
nuclei are stained with DAPI and that those nuclei staining red may be the result of deposition of
NiR dye, although this is unclear. This data suggests that there were notable differences in cells
viewed under Leica vs. Zeis confocal microscopes and that TCRNs are localized near the nucleus
but there is no clear evidence of nuclear delivery.
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blood stream with the concentrations of TCRNs that are used in the media in our in vitro
cytotoxicity experiments. Blood volume in animals is estimated using the following formula:
body weight (kg) x 7% = total blood volume (L) (40). For a typical mouse of about 20-40g, we
can calculate a total blood volume of 2.5mls. In our initial in vivo experiments, we delivered the
dye-loaded TCRN in a 0.1ml total volume. We also noted that the highest concentration of the
dye/TCRN solution that could be given to the animals without noticeable and consistent toxic
effects was 36µg/ml of DIR dye and 30mg/ml TCRN NPs. In a 20g mouse (blood vol ~1.5mls),
this translates to a dose of roughly 180µg/kg of dye or a blood concentration of dye equal to
2.4µg/ml. The lowest treatment administered in this experiment corresponds to a dosage of
60µg/kg of dye or a blood concentration of dye equal to 0.8μg/ml, which parallels studies of
these classes of drugs suggest as being well within a tolerable range.
Based on our in vitro data and the literature, we predicted that TCRNs carrying
fluorescent dyes would selectively target tumor cells, differentially depositing their contents into
the nucleus of carcinoma cells in a way that produces changes in fluorescent signaling. Here we
are only able to determine if dye is selectively deposited into the tumor tissue, and we infer from
our confocal studies that if the dye can be selectively focused in the tumor tissue, then it will
deliver its contents to the cells in the same manner noted in confocal microscopy. We measured
the fluorescent signal in the tumor using in vivo bioluminescent/fluorescent imaging with XIT at
various time points for one week. We found that the TCRNs are clearly being deposited in the
animals and that the particles persist in tissue without significant selectivity for the tumor tissue
(shown in Figures 15 and 16, and quantified in Figure 17).

40

Females w/o Tumors

Males w/ Tumors

Figure 15: Representative imaging of TCRN fluorescent signal (DiR) using Xenogen
Technology. These images represent fluorescent signal from the nanoparticles after 1 week of
incubation in athymic nude mice, either without tumor (Females w/o Tumors) or after injection
with M12 prostate cancer cells (Males w/ Tumors).
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Females w/ Tumors & Luciferin vs DiR
DiR (TCRN)

Luciferase (tumor)

Figure 16: Representative Xenogen images of female mice with tumors measured at 7
days. The fluorescent signal of xenograft tumors measured in female is shown for D-luciferase
(tumor fluorescence) and DiR (TCRN fluorescence), showing minimal overlap of nanoparticle
and tumor.
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Figure 17: Fluorescent signal measured over time using Xenogen Imaging Technology.
These graphs show the fluorescent signal of xenograft tumors measured in female (top) and male
(bottom) mice and recorded over time for 6 groups. The groups represent the various doses of
DiR dye delivered by the TCRNs. Mice with tumors (T+) are compared with mice lacking
tumors (T-). This data suggests that tissue deposition occurs without apparent selection of tumor
tissue.
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The in vivo Xenogen studies were subjected to complex statistical analysis using
sophisticated regression analysis with multiple variables and it was determined that the
differences noted between the treated and non treated animals was not significant. The strength
of our in vitro conclusions derives from the fact that we confirmed the results in one assay using
complementary assays. Statistical analysis for most of our in vitro experiments was moderately
limited because of the lack replicate experiments for the confocal and FACS analyses and
because Western densitometry is historically not quantitative. Importantly, the Western assays
were repeated, showing remarkable similarity in the overall expression levels for each cell type,
including breast and prostate cancer and the 2 normal cell types, BJ fibroblasts and ASCs. In
general, our results clearly show that the FR is expressed at higher levels in breast tumor cells
and to some degree in prostate tumor cells using 3 different techniques. The in vivo results, while
not statistically significant in terms of TCRN-tumor co-localization, were important and
definitive in showing localization of the TCRN in the animal and retention of the nanoparticle
for more than 5 days without liver toxicity and/or excretion by the mice. Taken together, our
results suggest that TCRNs have the ability to target the FR in tumor cells and be effectively
delivered at or near the nucleus of the cells, while showing stability after delivery into tumor
bearing animals.
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Chapter 4
Discussion

Even the briefest review of the current literature related to nantotechnology will convince
one that this field is explosive, one that is ripe with potential for advances especially in the area
of biomedical applications. Because the field is so young, much work needs to be done using in
vivo systems. Although ambitious, our proposal tried to confirm the in vitro experiments
associated with the TCRNs with in vivo experiments. There is much that can be said about these
NPs after our experiments, but there is still much more that needs to be done before definitive
conclusions can be made about them.
Our TCRN was tagged with a FA moiety in order to exploit the fact that many cancers
over-express FRs while most normal tissues express low to negligible levels. This FA/FR
interaction would help to show the clinical significance of the TCRNs. Furthermore, the
literature confirms that the over-expression of FRs on the surface of breast cancer cells is a
strong predictor of poor outcome in patients with breast cancer (12, 41), and so we would
anticipate that the SCP28 metastatic breast cancer cell line and the cell line from which it was
created (MDA-MB-231) would express higher levels of FR than the M12 prostate cancer cell
line.
Our experiments using Western and FACS confirm the variable expression of the FR in
all of our cells, while the confocal immunocytochemistry further verifies the presence of FR on
the cell surface in our tumor cell lines. While we unexpectedly show increased expression of FR
in the BJ fibroblast cells, previous results using normal cell types indicate that FR expression is
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luminal rather than on the cell surface. That said, additional experiments using FACS would
confirm this and ultimately lend credence to our assertion that FR, while expressed in normal
cells, would not be targeted by our TCRNs as FR expression is not on the surface of our cells.
Additionally, we found that FR is a cell surface protein that is difficult to isolate without
disrupting its confirmation, which is necessary for detection using our primary antibody. We
attribute much of the background observed in our FR Westerns to dimerization or fragmentation
of the FR protein or even FR complexing with other proteins. We plan to further confirm our
results using other antibodies.
Our FACS and Western assays also independently confirm the expression of the PSMA
protein in the M12 prostate cancer cell lines, which may, based on the literature (39), also be
exploited to bring FA into cells. By inference, this protein will be able to complement the FR in
transporting the FA tagged nanoparticples into the cell. Further characterization of the PSMA
protein using confocal-based immunocytochemistry will be done to determine PSMA’s ability to
be targeted by our TCRNs.
To further strengthen all of our assays, we plan to repeat this characterization using M12
and MDA-231 cells that have been engineered to over-express FR or with cells expressing a
dominant-negative mutant variant of the FR protein to reduce FR expression and function. Using
these FR engineered cells, we can begin to more reliably track the movement of the TCRNs into
the cells with confocal analysis, comparing high FR cells with cells that have either intermediate
FR expression or low FR expression. If the TCRNs perform as expected, we expect to see a
difference in the speed of dye uptake by the cells, as well as perhaps more clear evidence of
nuclear deposition. We will then track the TCRN uptake using Live Cell Confocal Microscopy
and record the timing of cellular uptake and association with the nucleus of the cell. To
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maximize the expression of the FR on the cell surface, we can also grow cells for a period of
time in FA deficient media, thereby allowing for more exposed, uncomplexed FR on the cell
surface.
Our confocal experiments indicate that the Nile Red dye loaded FA-labeled TCRNs can
be taken up by the cells and are able to associate with the nucleus while maintaining cell
viability. Preliminary results suggest very little, if any, nuclear deposition of dye into the cells,
yet there is significant association with the nucleus rather than just complete cytoplasmic
distribution. To further confirm specific subcellular delivery of the dye rather than simple
nuclear association of the dye/NPs, TCRNs have been designed to be tagged with Cy5 dye. This
TCRN labeling, together with the Nile Red or DiR internally loaded dye, would allow tracking
of the TCRN versus when and where the dye is released within the cell.
We find that the cells have a dose-dependent tolerance of the TCRNs, with optimal
concentrations consistent with what translates into tolerable and detectable doses in vivo. Our
results also show that cells do not survive well with higher concentrations of the TCRNs; yet our
experiments do not distinguish between the effects of the TRCN, the dye, or the combination of
dye and NP. To determine the relative contribution of each of these components we would need
to repeat the cytotoxicity experiments to include treatments with 1) the dyes alone 2) the empty
(dye free) TCRNs and 3) the dye loaded TCRNs without the FA moiety. Also, since the TCRNs
are responsive to changes in pH, we plan to vary the pH to confirm this function and to
investigate the influence pH has on the TCRN’s ability to affect the cell at various
concentrations.
We can also conclude from the in vivo experiments that the TCRNs can safely be
administered to animals intravenously and that they retain their ability to deposit their contents in
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tissues in an in vivo environment. We find that the TCRNs loaded with DiR are retained in the
animal for up to 7 days without being excreted through typical channels with no association with
the liver. We also observe tumor fluorescence using the SCP26 cells (luciferase), and after
TCRN injection, there is only modest overlap of the DiR from the TCRN and the luciferase from
the SCP26 cells. In the prostate cancer cells that were unlabeled (M12), we did find some
overlap with the tumor in a few of our mice, suggesting that the colocalization of TCRN with
tumor may be tumor-specific or that it could be dependent on the method and efficiency of
injection (see below). While much more work needs to be done, our efforts open the possibility
for further work with these NPs in future in vivo studies, providing more selective targeting after
alteration of the TCRN structure.
Since the clinical relevance of the TCRNs hinges on their ability to specifically localize
to the tumor tissue in live animals, we propose modifications of the in vivo component of our
experiment. First, the selection of cells for the xenograft tumor is critical. We discovered that the
SCP26 cells were over engineered with respect to their ability to express 2 kinds of luciferase
and a GFP, and the knockdown of Smad4 in these cells is achieved by expression of a shRNA
with GFP as selection marker, so the cells will constantly express GFP and thereby have green
fluorescence (34). Even though the DiR dye has a spectrum that is sufficiently distinct from the
GFP and we are able to specify filters that target the DiR, our cells may still produce background
levels of fluorescence that may confound the results. Because of this, we plan to use cells that
only express luciferase in addition to their increased expression of FR (MDA-MB-231luciferase), so that we will be able to control the luciferase fluorescence with the addition of Dluciferin. This fluorescent signal would enable us to restrict our ROI to the tumor and reduce
extraneous tissue that could dilute our signal. Our expectation is that this should enable us to see
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a measurably stronger signal in the cells with a higher expression of FR compared to those that
have their expression knocked down. To determine the precise location within the tumor, as well
as within the tumor cells, we would further evaluate the deposition of TCRNs by employing
confocal microscopy on the excised tumor tissue to detect both the dye from the TCRN and
luciferase.
We found that the administration of the TCRNs intravenously was quite tedious for our in
vivo studies. Since the Xenogen imaging chamber makes intravenous injections extremely
difficult, we needed to find a protocol that permits injections to take place outside of the chamber
in a more controlled environment to optimize success. This required us to eliminate the first posttreatment Xenogen reading (immediately post injection), which, based on our results, does not
show much of a measureable difference in fluorescent signal in any of our experiments. The loss
of this data point would not be as significant as the loss of animals incurred from rushed
injections resulting from perivascular leakage of drug, which often occurred during our
experiment. A clear intravenous injection also assures us that the dosage delivered is accurate
and free from extravascular background signaling. Preliminary tests using either tail vein and/or
retro-orbital injection methods both showed significant promise when done outside of the
Xenogen staging area.
In addition, we found significant bleeding of signal from one animal to another adjacent
animal as a result of high fluorescent signals from neighboring tumors. This confounded some
results where some tumors showed much higher signals than was to be expected based on tumor
size. Thus, shielding individual animal during imaging with a barrier divider will be done, which
will prevent radiant signal from adjacent animals, a problem we encountered during our imaging.
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Clearly, the ultimate confirmation of TCRN efficacy will come when the NPs are loaded
with an actual chemotherapeutic agent and subjected to the same in vitro and in vivo
experiments. These results, combined with our in vitro and in vivo preliminary data, will allow
correlation of cytotoxicity and tumor burden reduction with drug concentration, while additional
experiments using cells with alterations in FR expression will prove the importance of direct
tumor cell targeting in a living system.
In conclusion, despite a lack of specific nuclear deposition of TCRN contents in tumor
cells, our data are quite encouraging and suggest that the TCRNs have the potential to target
tumor cells using the FR and that the TCRNs are stable in vitro and in vivo. By refining and
expanding our in vitro experiments, we will be able to exercise greater control over all of these
variables in future experiments, translating these in vitro results to more definitive results in vivo
in order to determine the value of TCRNs in a therapeutic setting. In the end, if we can only
demonstrate nuclear association and not delivery, this finding would still be significant and
would suggest needed alteration in the TCRN to trigger nuclear delivery. Targeting FRexpressing carcinoma cells and focusing drug delivery to the nucleus will ultimately result in
greater efficacy with lower drug concentrations, especially with therapeutic compounds that
target and damage DNA as their mode of action.
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